I see trial execution, drug performance and money as three key issues to look out for.
I do wonder though, if the fully funded P1a/b trial gives them the information that they want.. even if the option subscriptions are low, will be that hard to stir up a capital raise off the back of even further promising clinical data.
I will have to look again at all the daya points we will see indications of in the P1.
I see trial execution, drug performance and money as three key...
-
- There are more pages in this discussion • 3,367 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.85 |
Change
-0.090(4.64%) |
Mkt cap ! $326.2M | |||
| Open | High | Low | Value | Volume |
| $1.93 | $1.97 | $1.85 | $312.6K | 163.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 8804 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.89 | 500 | 1 |
View Market Depth
| Last trade - 15.56pm 16/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |